All News

WOTY- Podcast-Howson

Woty-Podcast-Sibley

Just two months after the purchase of Wyeth, Pfizer breaks its research division into two-one for large molecules and vaccines, and another for small molecules-with Wyeth and Pfizer execs at the helms.

Launching a product? Your competition likely plans to interfere. Here's how to counter a counter-launch.

Protecting Sensitive Information in Life Sciences Organizations: Top Three Misconceptions that Put Companies at Risk-Brainloop Whitepaper

In addition to overhauling healthcare, Congress is weighing proposals for updating FDA policies and expanding access to drugs.

Now that Vyvanse, Shire's innovative ADD drug, has been approved for adults, the company needs help to quickly roll out a complex message to neurologists. Its solution: a partnership that takes advantage of GSK's CNS muscle.

Compliance woes and stingy insurance providers are walloping the pharmaceutical industry. But now another nuisance is rearing its ugly head, as a high number of patients are ignoring their doctor's orders and dropping their prescriptions on purpose.

Unsolicited advice for FDA's next leader: Keep it real, fight popular delusions, and somehow, please, defend the agency.

Reflector ponders recent events in the battle against counterfeit drugs.

After repeated requests for additional study information, the wait has paid off: Lilly was approved to sell its bipolar drug Symbyax for treatment-resistant depression.

December 2008 BPA Statement

With the economy in turmoil, pharmaceutical manufacturers are reassessing where and how they spend their advertising dollars.

Pharm Exec sits down with Kathryn Metcalfe, Pfizer's new vice president of corporate reputation and policy communications to discuss the new position, the perception of pharma among laypeople, and what needs to be done to boost public opinion of the drug industry.

Reflector ponders the growing gap between the US and Europe's vision for the future of drug marketing.

Podcast:Women of the Year-professor to president. Anhal Purohit

The morning's other big M&A news comes out of the Bay Area biotech industry, where Gilead Sciences announced that will purchase CV Therapeutics for $1.4 billion.

Lawyers from Duane Morris LLP offer their take on the Supreme Court's groundshaking preemption decision

After months and months of back and forth over the true value of Genentech, Roche finally got the good news it's been looking for: Genentech's board of directors, this morning, approved Roche's latest offer of $46.8 billion ($95 per share) to acquire all shares of the biotech giant.

WOTY-How the Award has changed the face of the industry.

The Merck acquisition of Schering-Plough may have surprised few, the approach has raised some eyebrows. Rather than buy the company outright, Merck going through a convoluted reverse merger deal to keep Schering's licensing deals secure. Was it the right move?

Manhattan Research singled out type 2 diabetes sufferers and their online search patterns; it turns out diabetes patients are less likely to confront doctors about branded drugs they?ve seen in DTC ads, yet more apt to take Lipitor.